High-risk prostate cancer (HRPC) has higher recurrence potential and multimodal treatment offers better outcomes in this population.
The aim of this article is to comprehensively present the multimodal therapeutic options for HRPC. Review of the literature on HRPC with a literature selection based on evidence and practical considerations. Therapeutic options for localized HRPC are radio hormone therapy and radical prostatectomy with extended lymph node dissection. Selection of patients is essential to define individualized therapeutic strategy and timing for every modality should come as a consensus of medical supported evidence. Accurate patient selection and multimodal treatment offer the best therapeutic option in HRPC.
Written by:
Rozet F, Audenet F, Sanchez-Salas R, Galiano M, Barret E, Cathelineau X. Are you the author?
Department of Urology, Institut Montsouris, 75014 Paris, France.
Reference: Expert Rev Anticancer Ther. 2013 Jul;13(7):811-8.
doi: 10.1586/14737140.2013.811149
PubMed Abstract
PMID: 23875659
UroToday.com Prostate Cancer Section
